Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept
Authors:
- Robert BissonnetteRBRobert Bissonnette
- Chantal BolducCBChantal Bolduc
- Yves PoulinYPYves Poulin
- Lyn GuentherLGLyn Guenther
- Charles W. LyndeCLCharles W. Lynde
- Catherine MaariCMCatherine Maari
- 1 August 2010
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 63 (2) , 228-234
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- From biologic to biologic to biologic: Lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasisAustralasian Journal of Dermatology, 2008
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008
- Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)British Journal of Dermatology, 2007
- Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologicsJournal of the American Academy of Dermatology, 2007
- Infliximab in the treatment of psoriasis in patients previously treated with etanerceptJournal of the American Academy of Dermatology, 2007
- A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBritish Journal of Dermatology, 2005
- Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trialJournal of the American Academy of Dermatology, 2005
- Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert PanelJournal of Cutaneous Medicine and Surgery, 2004
- Etanercept as Monotherapy in Patients with PsoriasisNew England Journal of Medicine, 2003